

Adler et al.

toxin. Annu Rev

Tetanus toxin is a
ly depend on zinc.

BR, Montecucco
proteolytic cleav-

nnu Rev Physiol

ic delivery by pH-

6

Botulinum Toxin Type B: Experimental and Clinical Experience

Elizabeth Moyer and Paulette E. Setler
Athena Neurosciences, Inc., South San Francisco, California

INTRODUCTION

Botulinum toxins BTXs (types A, B, C1, D, E, F, and G) are among the most potent toxins known. The toxins have been studied since the turn of the century, initially to gain an understanding of botulism, a form of food poisoning. Later, they were studied as something of a curiosity, because of the uniquely long-lasting and specific muscle paralysis induced by minute amounts of the toxins. Today, that "curiosity" is beginning to be exploited in the treatment of movement disorders such as blepharospasm and torticollis.

The type B toxin is possibly the first BTX ever discovered, having been identified as the causative agent in a 1895 outbreak of botulism (1). In this incident, which took place in Eliezelles, Belgium, three musicians died. The cause of death appeared to be a neuroparalytic toxin produced by an anaerobic, spore-forming bacterium. When these bacteria were cultured, the culture medium was found to cause botulism-like toxicity in a variety of experimental animals, by various routes of administration. It was later found that this toxicity was not prevented by protective antisera produced against toxin from bacteria isolated from a different incident of botulism, in Germany. Similarly, antisera protective against the Belgian toxin were not protective against the German toxin, although the bacteria that yielded the two toxins, and the toxicity they produced, were similar (2). Although both cultures were later lost, it is believed that the second type of *Clostridium botulinum* was a strain of what we today call type A (3). Thus began a long list of publications related to the bacteria and their toxins: there are far more publications related to BTXs in the following years than there have been documented cases of human botulism.

STRUCTURE OF BOTULINUM TOXIN TYPE B

Toxin-Nontoxic Protein Complex

As isolated from the bacterial culture medium, type B toxin (like type A toxin) is found combined with nontoxic proteins. In the case of type B toxin, stable complexes of two different sizes are formed. These complexes have sedimentation coefficients of 16 and 12 S, and are called L (large) and M (medium), respectively. (The uncomplexed, pure toxin protein is sometimes called the S, or small, form.) The M complex contains nontoxic proteins that reportedly do not have hemagglutinin activity (4). The larger of the two types of complex (L form, about 450-500 kD) contains other protein(s), in addition to these nontoxic proteins, that do have hemagglutinin activity. These toxin-nontoxic protein complexes are not held together by covalent bonds and can reversibly dissociate, releasing the toxin protein, depending on the pH and ionic strength of the solution. Both pH greater than 8 and low ionic strength favor dissociation of the complex. There is some antigenic cross-reactivity and sequence homology between the hemagglutinins of the type A and B toxins (5). However, neutralization of type B hemagglutinin activity with a type A antitoxin prepared against a type A toxin-hemagglutinin complex does not neutralize the type B toxin (6). Formation of an association complex with the nontoxic proteins appears to stabilize the activity of BTXs, perhaps by helping to maintain a necessary secondary or tertiary structure (7). It is presumably for this reason that the only currently commercially available BTX for clinical use, type A, is formulated in the form of a toxin-hemagglutinin-containing nontoxic protein complex, rather than as a formulation of the pure toxin.

Toxin

The type B toxin is synthesized by the bacteria as a single protein chain that has low activity until proteolytically cleaved. This cleavage—"nicking"—occurs endogenously by the action of bacterially produced protease(s) (8,9). Strains that activate most of the produced toxin are termed "proteolytic," such as the strains "Beans" and "Okra." Full activation of the toxin can also be achieved artificially by trypsinization: the bacterial nicking protease and trypsin cleave at or very near the same site. The amount of endogenous activation varies according to the *C. botulinum* type B strain and the fermentation conditions. Even under the best conditions, using the proteolytic strains, both nicked and unnicked toxin may be produced (10).

The nicked toxin has a molecular weight of about 150,000 kD and is composed of a heavy and light chain, held together by a disulfide bond and noncovalent bonding. Reduction of the disulfide bond causes a separation of the chains and loss of toxicity (11): neither chain by itself is toxic. The molecular weights of the two chains are about 100,000 and 50,000 kD, respectively (12). The nicking site is one-third of the length of the single chain, and the light chain is formed from the amino-terminal portion. The amino-terminal sequences of the unnicked type B are identical to the amino-terminus of the light chain of the nicked toxin (13). Whether this proteolytic cleavage termed "nicking" is sufficient to activate the toxin remains controversial (14).

Until very recently, only limited structural information about the type B toxin was available. Most of this information was derived by inference from antigenicity studies (although there was a limited amount of sequence data obtained from fragments of the toxin). The antigenicity data suggested significant differences between the various types

Experience with

of BTX in its significant and by the antigenic group and by characteristics growth). Variations primarily on the between type B been reported, (17). However, toxin is protect bacteria (18).

The structure produced by the two classes to be compared homology exist of the purified polyclonal anti. This implies that botulinum toxin not immunogenic implications of in understanding

Recently, the toxin, from two for the other type with the sequence produced by the A toxin and 3% hydrophobicity suggests that for This region in membrane (see hypothesized to end, is one of portion of the various types of

The light chain 32% homology. Surprisingly, the equivalent portion BTXs have a light toxin. Analysis of toxin also indicates sequence is type that such activation

A toxin) is found in complexes of two subunits of 16 and 12 kD. The 16 kD subunit is a complexed, pure toxin and the 12 kD subunit contains nontoxic protein. In addition to these, a nontoxic protein is associated, releasing a toxin. Both pH greater than 10 and some antigenic differences between the type A and B toxins with a type A toxin do not neutralize the toxin in proteins appears necessary secondary or tertiary structure of the pure toxin.

chain that has low molecular weight and is endogenously produced by most of the bacteria and "Okra." Full activity: the bacterial toxin. The amount of toxin in the B strain and the proteolytic strains,

is composed of a covalent bonding. The amount of toxicity (11): are about 100,000 units of the single toxin. The amino-terminal of the light chain of the toxin is sufficient to

type B toxin was antigenicity studies in fragments of the toxin in the various types

of BTX in terms of their amino acid sequences. The antigenic differences are so significant and reproducible, in fact, that the botulinum bacteria are primarily classified by the antigenic specificity of the toxins they produce, with additional subdivision by group and by strain. Assignment to group is based on slight differences in culture characteristics (proteolytic ability, heat resistance of spores, optimal temperature for growth). Various type B bacterial strains within these groups have been described, primarily on the basis of the first source of culture. Some amino acid sequence differences between type B toxin produced by different strains of type B *C. botulinum* (15,16) have been reported, and even, in some cases (depending on the strain), antigenic differences (17). However, neutralizing type B antitoxin raised against one strain of type B bacterial toxin is protective against type B toxin produced from a variety of strains of type B bacteria (18).

The structure of the type B toxin is loosely related to that of tetanus toxin, also produced by bacteria of the genus *Clostridium*. The general size and subunit structure of the two classes of toxin are similar, and some aspects of mechanism of action also appear to be comparable. Antipeptide antibody binding studies indicate some limited sequence homology exists between various BTXs and tetanus toxin, particularly in specific regions of the purified (possibly partially unfolded) proteins (19). However, human and mouse polyclonal antibodies that neutralize tetanus toxicity do not cross-react with the BTXs. This implies that the homologous sequences in the primary structure of tetanus and botulinum toxins are generally short amino acid segments that are either not accessible or not immunogenic in the native conformation state of the molecules. The functional implications of the sequence homology are not yet understood but may be of great interest in understanding the mechanism of action of the various toxins.

Recently, two groups (20,21) have reported sequence information about the type B toxin, from two different type B strains. Comparable information was already available for the other types of BTX and for tetanus toxin. A comparison of the type B sequence with the sequence of these other toxins indicates that the heavy chain of type B toxin produced by the Danish strain has a sequence homology of 48% to the heavy chain of type A toxin and 35% homology to the equivalent portion of the tetanus toxin sequence. A hydrophobicity plot comparison of various strains of BTX types and of tetanus toxin suggests that for all of them, there is a conserved hydrophobic region in the heavy chain. This region may be important for translocation of the toxin across the extracellular membrane (see below). In contrast, the portion of the toxins that has previously been hypothesized to be most important to receptor binding, the heavy chain carboxyl-terminal end, is one of the regions of most divergent sequence. The sequence difference in this portion of the toxins could explain the specificity of receptor binding reported for the various types of clostridial toxins.

The light chain of the type B toxin produced by the Danish and Okra strains have 31-32% homology to the light chain of type A toxin as reported by these two groups (20,21). Surprisingly, the type B toxin was also found to have a 50-52% homology to the equivalent portion of the tetanus toxin sequence. The light chains of type A, C1, and D BTXs have a lower (roughly 30%) homology to the equivalent portion of the tetanus toxin. Analysis of the light chain sequences of the various types of BTX and of tetanus toxin also indicates a highly conserved region that contains a histidine-rich sequence. This sequence is typical of the active site of metalloproteinases, and it is tempting to assume that such activity could have some role in the intracellular action of the toxins.

PHARMACOLOGY AND TOXICOLOGY OF BOTULINUM TOXIN TYPE B

Mode of Action

Botulinum toxins, including type B toxin, probably act through a three-step process: extracellular binding onto the neuron, internalization, and intracellular poisoning (22). Binding appears to occur as a result of an interaction with specific acceptors on the surface of the presynaptic motor nerve terminal membrane (23). Using radiolabeled toxins and various *in vitro/ex vivo* models, distinct acceptor sites on the presynaptic terminal for some of the toxins have been found. Using rat cerebrocortical synaptosomes, sites specific for types A, B, E, and F have been reported: the sites are saturable, and toxins of one type bind weakly, if at all, to the acceptors of another type (24). In studies using mouse hemidiaphragms, type B toxin was not found to affect type A binding at all. (However, Black and Dolly reported that a large excess of type A toxin slightly reduced type B toxin binding to mouse hemidiaphragms *in vitro* [25]). Evaluating binding affinities with rat brain synaptosomes, Evans *et al.* found that there are two populations of acceptors for type B toxin: a smaller number of high-affinity sites ($K_D = 0.3-0.5$ nM; B_{max} about 30-60 fmol/mg protein), and a larger number of low-affinity sites ($K_D = 16-21$ nM; $B_{max} > 3000$ fmol/mg protein) (26). In mouse hemidiaphragms, the total density of acceptors for type B toxin ($627 \pm 21\%$ sites/ μm^2) is approximately four times that of acceptors for type A toxin ($152 \pm 20\%$ sites/ μm^2) by electron microscope autoradiography (25).

Binding of the various BTXs to neurons is mediated by the carbonyl end of their heavy chain (27). Both the single-chain unnicked toxin and the heavy chain of type B toxin bind to rat brain synaptosomes, and the heavy chain is a potent inhibitor of the binding of the single chain, whereas the light chain is much less effective (28). Preincubation with the heavy chain of type B toxin antagonizes the *in vitro* paralysis of mouse hemidiaphragm induced by the active type B dichain (29).

Botulinum toxin binding to the presynaptic nerve membrane may involve both membrane determinants containing sialic acid (probably gangliosides) and one or more proteins (acceptor/receptor proteins) on the neuronal surface membrane (30). The acceptors for BTXs have not yet been isolated or characterized, and the evidence for this double receptor hypothesis is indirect, particularly for the role of gangliosides. Gangliosides, but not other membrane lipids, inactivate BTX *in vitro* and *in vivo* (31). Certain lectins with affinity for sialic acid-containing sugars reduce the binding of BTXs to brain membranes and reduce the neuromuscular blocking activity of the toxins (32). The specific gangliosides involved may differ between the various types of BTX. Type A toxin binds avidly to GQ_{1b} gangliosides, whereas type B toxin binds less efficiently to GQ_{1b} ganglioside (33), and more efficiently to GD_{1a} and GT_{1b} gangliosides than type A toxin (34). The results of these studies are highly dependent on the pH and ionic strength of the medium, however. Less is known about the protein component of BTX binding to neurons. It is presumed that there is such a component, and that it has functional significance, by analogy to other, better-characterized receptors. Also, toxin binding to synaptosomal membranes is affected by pretreatment of the membranes with either neuraminidase (attacking the sialic acid residues of the gangliosides) or proteases (35). This combination of neuronal-specific phospholipid and receptor protein requirements may help explain the very specific neuronal affinity of the botulinum toxins.

Binding of the toxin to its acceptor is neither sufficient nor, under experimental conditions, necessary to cause paralysis. Intracellular toxicity of the toxins can be

Experience with

observed using r
injection of the
Similarly, there:
antibody is prob

A number of
the toxin is inte
studies using m
toxin bound to
therefore presu
More direct evi
showed that the

The internaliz
require the pres
complex is take
toxin then some
extracellular mil
toxin. As a resu
interact more co
(40). It is hypot
inserts into the r
molecule into th
model, it appear

Inhibition of
(42). The mech
B, but it is ge
receptor occupa
paralysis induce
likely that the t
slowly reversed
enzymatic mecl
mechanism of t
toxins have died
to those of BT.
binding and inte
these cases, the
types C1 and
synaptosomes (activity was ass
there is some
sequence in the
metalloproteins
loproteases rep
experiments us
not shown any
(45). These re
loprotease acti
chelating agent
and calcium fix

Moyer and Seiler

JUM TOXIN

a three-step process: lular poisoning (22). ceptors on the surface fiolabeled toxins and synaptic terminal for osomes, sites specific and toxins of one type studies using mouse ing at all. (However, reduced type B toxin ing affinities with rat ions of acceptors for 5 nM; B_{max} about 30- = 16-21 nM; B_{max} > 1 density of acceptors s that of acceptors for radiography (25). nyl end of their heavy n of type B toxin bind : of the binding of the reincubation with the ouse hemidiaphragm

ay involve both mem- and one or more pro- te (30). The acceptors idence for this double des. Gangliosides, but). Certain lectins with s to brain membranes 2). The specific ga- . Type A toxin binds iciently to GQ_{11} gan- han type A toxin (34). l ionic strength of the t of BTX binding to that it has functional Also, toxin binding to embranes with either les) or proteases (35). r protein requirements inum toxins. r, under experimental of the toxins can be

Experience with Botulinum Toxin Type B

75

observed using methods that bypass the binding step. Such methods include intracellular injection of the toxin into *Aplysia* ganglia (36), or using permeabilized cells (37). Similarly, there appears to be a time lag between in vitro binding of the toxin, when toxin antibody is protective, and subsequent paralysis (38).

A number of studies, including the histological studies cited above, have shown that the toxin is internalized after binding to the cell surface. For example, in vitro kinetic studies using mouse hemidiaphragm and antibodies to BTX revealed that after a while, toxin bound to the cell surface became inaccessible to the antibodies. The toxin is therefore presumably internalized (thus inaccessible) before the onset of paralysis (39). More direct evidence was provided by electron microscopy autoradiography, which showed that the toxin appeared to be internalized, in vacuole-like structures (25).

The internalization process is not completely understood, but, like binding, seems to require the presence of the heavy chain of the toxin. After binding, the toxin/receptor complex is taken into an endosome by an active, temperature-dependent process, and the toxin then somehow enters into the cytosol. The endosome has a lower pH than the extracellular milieu, and the lower pH appears to induce a conformational change in the toxin. As a result of the conformational change, hydrophobic domains are exposed that interact more extensively with lipids, as demonstrated using a liposome model system (40). It is hypothesized that the highly conserved hydrophobic region of the heavy chain inserts into the neuronal membrane and forms a channel, allowing some or all of the toxin molecule into the cell. At least in the case of the type B toxin, using a planar lipid bilayer model, it appears that at acidic pH, the heavy chain is capable of forming channels (41).

Inhibition of neurotransmitter secretion is probably caused by a site on the light chain (42). The mechanism by which intracellular poisoning is achieved is unknown for BTX-B, but it is generally believed to involve enzymatic activity and not mass action or receptor occupancy effects. This hypothesis is attractive for two reasons. First, since the paralysis induced by minuscule amounts of the toxin lasts for weeks or months, it seems likely that the toxin must act on an intracellular component by some means that is only slowly reversed. Such changes would most likely be catalyzed by an enzyme. Second, an enzymatic mechanism seems likely by extrapolation from the more clearly understood mechanism of action of other bacterial toxins, such as ricin and diphtheria toxin. These toxins have dichain structures and apparent structure/function activities generally similar to those of BTXs. The heavy chains of ricin and diphtheria toxin are also involved in binding and internalization, and the light chain is the portion with intracellular activity. In these cases, the activity has been demonstrated to be enzymatic (43). Botulinum toxins types C1 and D have been shown to ADP-ribosylate a membrane protein in mouse synaptosomes (44), but until recently there was no convincing evidence that enzymatic activity was associated with the other BTX serotypes, including type B. As noted above, there is some recently discovered homology between a segment of the amino acid sequence in the central core of the light chain of the various BTXs and zinc-dependent metalloproteinases. This sequence contains a histidine-rich motif that for the metalloproteinases represents a zinc-binding site and part of the active site of the protease. Initial experiments using type A toxin mutants in which the histidine site has been affected have not shown any effect of the mutations on the effectiveness of BTX in *Aplysia* neurons (45). These results therefore do not support the hypothesis that this putative metalloprotease active site is important to BTX intracellular activity. At the same time, chelating agents such as 1,10-phenanthroline, which are capable of stripping zinc, iron, and calcium from proteins, are capable of inactivating BTXs including type B toxin (46).

All of the BTX serotypes prevent both spontaneous and evoked quantal release of acetylcholine from the presynaptic neuromuscular junction. However, the intracellular mechanism by which this effect is achieved appears to be different. A series of studies has been performed that emphasizes these differences, in synaptosomal preparations, in phrenic nerve-hemidiaphragms, and also in a double-poisoning experiment using types A and B toxins on a triangularis sterni nerve-muscle preparation (47). These studies all suggest differences between the toxins in terms of the response to pharmacologic manipulation of calcium ion movement, or to microtubule-dissociating drugs.

The most frequently studied difference between the toxins is reversibility of acetylcholine release inhibition by the aminopyridines. These agents increase impulse-evoked Ca^{2+} influx by blocking presynaptic potassium channels. As a result, neurotransmitter release can take place. Aminopyridines reverse the poisoning induced by types A and E (48), but the effect is greatest with type A toxin. The poisoning induced by B, D, and F is not reversible by aminopyridines. An increase in extracellular calcium or use of a Ca^{2+} ionophore, A23187 (49), or guanidine more effectively reverses the effects of type A than of type B, C, or E toxins (50). When synaptosomes were preincubated with microtubule-dissociating drugs, there was a reduction of type B (but not of type A) toxin inhibition of neurotransmitter release. This effect did not appear to be related to prevention of binding or internalization of the toxin (49). The most probable explanation for these differences is that the toxins act at different steps in the process that results in neurotransmitter release.

Comparative Muscle Paralytic Efficacy

Relatively few studies have been reported evaluating the *in vivo* muscle paralytic potency of BTX types other than type A. Usually, these studies have been performed using rats, a species apparently particularly resistant to type B toxin (see below), or rat tissues. In a study by Burgen et al. using a rat *in vitro* phrenic nerve-diaphragm preparation, when the toxin was added to the perfusate of the *in vitro* system, it took amounts of type B toxin "... about 500 times greater than the amount of type A toxin required to produce a similar rate of paralysis. When, however, the phrenic nerve-diaphragm preparation was obtained from young guinea-pigs (150-200 g.) typical neuromuscular block followed the addition of 2000 units/ml. of either type A or type B toxin. There were no marked differences in the latent period or rate of paralysis between types A and B toxins on this preparation. The guinea pig is known to be susceptible to type B toxin. ..." (51).

Another study, by Sellin et al. (52), found that it required 1200 mouse LD_{50} of type B toxin to prevent measurable evoked potentials in a rat *ex vivo* nerve-muscle preparation. The difference between these two studies in terms of the effective dose for type B toxin-induced paralysis may be that Sellin et al. administered the toxin subcutaneously, above the tibialis anterior muscle *in vivo*, then later removed the extensor digitorum longus muscle to measure *in vitro* electrophysiological effects, while Burgen et al. added the toxin to the perfusate of their *in vitro* preparation.

In rats, no toxin studied has been found to be as potent as type A. Type E (53) and F (54) toxins have also been studied with the same model, and it was found that the dose and duration of the paralysis induced in rats was less than with type A. Unfortunately, given the species-specificity of the various toxin types, rodent studies must be considered inconclusive with respect to predicting the relative clinical potency of the various types of BTX.

Experience

For this nonhuman trapezius, : digitorum l 80 U/mouse these studies the evoked paralysis in reduction of APB and l reduction of 11 animals by BTX-B therapeutic by approximately obtained in no measurements of the not determined (abductor p of paralysis lower in es BTX-B injection the end of trapezius markedly different both muscle

Reinject in the evoked of the second did not induce completely drug.

For type occur after injecting this as expected and a form twitch red was observed was also of collateral s reported in

The mechanism unknown, b This conclusion review articles rabbits, evaluation

Ioyler and Seiler

ant release of the intracellular contents of studies has been made in preparations, in using types A and B. These studies all showed a toxicologic manipu-

lability of acetylcholine-evoked neurotransmitter release by types A and B. Types B, D, and F are used in a Ca^{2+} release assay. Effects of type A toxin incubated with type A toxin related to prevention of explanation for results in

paralytic potency was determined using rats, a rat tissue. In a rat tissue, when the type B toxin was injected to produce a preparation was followed the type B toxin were no marked effects on this

LD₅₀ of type B toxin preparation. For type B toxin-antagonism, above digitorum longus et al. added the

type E (53) and F that the dose and duration, given to be considered various types of

Experience with Botulinum Toxin Type B

77

For this reason, we have undertaken to study the paralytic efficacy of BTX-B in normal nonhuman primates. In these studies, the toxin was injected into three muscles: the trapezius, the abductor pollicis brevis (APB) muscle of the thumb, and the extensor digitorum brevis (EDB) muscle of the foot. Doses injected into muscles ranged from 5 to 80 U/muscle (1 U is the dose equivalent to a mouse intraperitoneal LD₅₀ dose). Efficacy in these studies was measured electrophysiologically, by a decrease in the peak amplitude of the evoked compound muscle action potential. Botulinum toxin type B was found to paralyze injected muscles effectively. At 2 weeks after the initial injection, there was a reduction of maximal muscle electromyographic (EMG) amplitude of 80% or more in the APB and EDB muscles injected at all of the doses tested, in all subjects. A similar reduction of maximal trapezius muscle EMG amplitude was observed after 2 weeks in 10 of 11 animals injected with doses greater than or equal to 80 U/muscle. Muscles paralyzed by BTX-B recovered over time. All of the muscles injected with doses in the estimated therapeutic range had evoked compound muscle action potentials that could be measured by approximately 3 months after the last injection. This result is in contrast to results obtained in the same animals 2 weeks after the initial injection, when several muscles had no measurable evoked compound muscle action potentials. On the basis of visual estimates of the mass of the three muscles tested (the actual mass of the injected muscles was not determined), it appeared that for any given dose, the smaller the muscle mass (abductor pollicis brevis < extensor digitorum brevis < trapezius), the longer the duration of paralysis. Evoked compound muscle action potentials in the injected APB tended to be lower in each animal at each injected dose than in the trapezius, although the dose of BTX-B injected into the APB was one-fourth of the trapezius dose. Similarly, whereas at the end of the study the evoked compound muscle action potentials in the APB and trapezius muscles in the lowest-efficacy dose group were no longer statistically significantly different from baseline values, the evoked compound muscle action potentials of both muscles in the highest-efficacy dose group were significantly less than at baseline.

Reinjection of recovering muscles with a second dose of BTX-B resulted in a decrease in the evoked compound muscle action potentials measured 2 weeks after administration of the second dose. The response of the muscle injected with the second dose of the drug did not indicate a cumulative effect of the doses: reinjected muscles were neither more completely paralyzed nor longer paralyzed than muscles injected with a single dose of the drug.

For type A toxin, histochemical studies have been made, evaluating the changes that occur after injection of the toxin. Duchon (55) performed a series of such studies, injecting the type A toxin into the calf muscles of mice. Typically, the muscles atrophied, as expected from a functional denervation. Also observed was a sprouting of nerve fibers and a formation of new end plates, which occurred more rapidly in the soleus (a slow-twitch red muscle) than in the gastrocnemius (a fast-twitch white muscle). The sprouting was observed to take place preterminally as well as terminally, and collateral sprouting was also observed. Over time, as the muscle recovered function, the number of these collateral sprouts decreased. Similar sprouting after type A toxin injection has been reported in frogs (56), primates (57), and humans (58).

The mechanism by which the type B toxin muscle paralysis is reversed over time is unknown, but it may be assumed to be similar to recovery after type A-induced paralysis. This conclusion is based on results of a study submitted for publication, cited in a recent review article (59). The review article reports that this study was performed in albino rabbits, evaluating histochemical changes (acetylcholinesterase stain, muscle fiber size,

and ATPase staining) after injection of either BTX-A or a "crude preparation" of type B toxin." The denervation indicated by histochemical staining and fiber size analysis appeared transient and lasted for about 3 months for both type A and B toxins."

Comparative Toxicity Data

Type B toxin is known to be toxic for humans, as noted in the introduction, when ingested in poorly processed foods. In the United States, most reported cases of botulism have been related to either type A or type B toxin: together they accounted for 91% of the cases of known toxin-type botulism reported to the Centers for Disease Control from 1970 to 1979. Type A toxin is responsible for twice as many cases of food botulism as type B (60). Of the two types of human botulism, type A is considered to be the more severe (61). Human oral toxic doses are difficult to estimate from these oral food poisoning reports, however, and the clinically toxic dose, even by the oral route, is unknown.

Typically, it takes 1 to 2 days for the symptoms of botulism to develop. The highest cranial nerves are affected first, causing medial rectus paresis, ptosis, and sluggish pupillary response to light. They are followed by the lower cranial nerves, then the peripheral motor neurons, finally and often fatally including those that innervate the respiratory muscles. Effects on peripheral muscles are not observed in the absence of ophthalmic changes: in one study of an unusually large outbreak of type B botulism (53 people were hospitalized), all of the patients who later experienced respiratory difficulty or peripheral muscle weakness first demonstrated cranial nerve impairment (62). In some cases, patients have signs of autonomic nervous system dysfunction: constipation, distention of the urinary bladder, and decreased salivation and tearing (63). Blood counts, urinalysis, and clinical chemistry values are normal in botulism, unless there are secondary complications (the most frequent of which is pneumonia associated with respiratory muscle paralysis) (64).

A definitive diagnosis of botulism can be made by electromyography (EMG). In muscles weakened by botulism, the amplitude of the compound muscle action potential is reduced in response to a supramaximal stimulation of the nerve (65). In partially paralyzed muscles, the response to a double stimulus shows an incremental response (66). However, in severely paralyzed muscles, the neuromuscular blockade may be so complete that repetitive stimulation may not be effective (67). Other EMG measurements appear to remain normal in botulism patients: in a report of an extensive EMG study made in a single type B botulism patient, the latency of facial nerve and upper limb motor and sensory conduction velocities remained normal (68).

Within- and between-species toxicity data from various sources for the type B toxin are difficult to compare, for several reasons:

1. Different end points (minimum lethal dose versus LD_{50}); reference species used (in some cases, the data are expressed as mouse lethal units, in other cases, as guinea pig lethal units).
2. Different normalizing units: units per milligram total nitrogen, per absorbance at different wavelengths, per milligram protein measured using different assays. (Inter-conversions between these units of measure are approximations at best.)
3. Probable differences in the purity of the toxin and/or percentage nicked versus unnicked toxin in the test material.
4. Differences in route of administration: intraperitoneal, subcutaneous, intravenous, oral, even inhaled.

Experience

However, a species-specific more sensitive

Route of amount of not be sure

Poisoning depend escape d toxin to absorptio transport resist sp

In this paper the amount depending Table 1. Not significantly typically us BTXs. Dose not appear BTXs.

A great the rat, in injection) is LD_{50} type Sellin et al.,

Table 1. Routes of In

Route
Intravenous
Intra-arterial
Intramuscular
Intracerebral
Intrapulmonary
Occipital
Subcutaneous
Eye anterior
Intraperitoneal
Intrascapular
Intragastric
Intrarectal

Source: From 1

Moyer and Seiler

ration" of type B
ber size analysis
B toxins."

on, when ingested
tulism have been
% of the cases of
om 1970 to 1979.
: type B (60). Of
ere (61). Human
eports, however,

lop. The highest
is, and sluggish
nerves, then the
at innervate the
the absence of
B botulism (53
iratory difficulty
ent (62). In some
stipation, disten-
) Blood counts,
there are second-
with respiratory

phy (EMG). In
ction potential is
n partially para-
l response (66).
y be so complete
ments appear to
study made in a
limb motor and

type B toxin are

species used (in
es, as guinea pig

r absorbance at
nt assays. (Inter-
best.)

e nicked versus

us, intravenous,

Experience with Botulinum Toxin Type B

79

However, as reported even in the earliest studies by van Ermengem, there appears to be species-specificity in terms of the relative sensitivity to type B toxin, with guinea pigs more sensitive to type B toxin than rats or rabbits (69).

Route of administration also appears to make a difference, at least in terms of the amount of the drug required for toxicity by various routes of administration. This should not be surprising, as pointed out in a paper by Lamanna (70):

Poisoning of an animal by any mode of exposure to a toxin, including inhalation, will depend on the outcome of a sequence of four events: first, the capacity of the toxin to escape destruction inherent in the techniques of application; second, the capacity of the toxin to get to and to remain at the site of deposition where effective systemic absorption can take place; third, the capacity of the toxin after absorption to be transported to the primary site of poisoning; and fourth, the capacity of the toxin to resist specific or nonspecific forces of detoxification on route to the sites of action.

In this paper, for type B toxin, the rapidity of death (presumably inversely proportional to the amount of toxin required for overt toxicity) in rabbits appeared to differ significantly depending on the route of administration. The data, taken from an older article (71), are in Table 1. Note that time to death after injection of the toxin by the intraperitoneal route is significantly longer than after intramuscular injection. Intraperitoneal injection is the route typically used with mice to standardize the relative potency of various preparations of BTXs. Despite differences in the route of administration, the symptoms of poisoning were not apparently different. This is also consistent with toxicity data available for other BTXs.

A great difference in the relative toxicity of type A and type B toxins was also seen in the rat, in the study by Burgen et al. described above, where the LD_{50} (intraperitoneal injection) in 200 g rats of the two toxins were found to be approximately as follows: rat LD_{50} , type A toxin = 25 mouse LD_{50} ; rat LD_{50} , type B toxin = 10,000 mouse LD_{50} . Sellin et al., in the comparable study, found that doses of type B toxin of 5000 mouse LD_{50}

Table 1 Order of Rapidity of Death of Rabbits by Various Routes of Injections of Botulinum Toxin Type B

Route	Time of death		
	days	hr	min
Intravenous		2	25
Intra-arterial		2	45
Intramuscular		4	30
Intracerebral		4	35
Intrapulmonary		5	0
Occipital		6	10
Subcutaneous		7	45
Eye anterior chamber		8	15
Intraperitoneal		9	5
Intrasciatic		10	53
Intragastric		33	45
Intrarectal	4	9	0

Source: From Legroux, Levardit and Jéramet, 1945, as cited in Ref. 70.

caused debilitation or death (in contrast, only 20 mouse LD₅₀ units of type A toxin caused similar toxicity). In the Lamanna paper, data were also given comparing the sensitivities of guinea pigs to different types BTX administered by various routes, as listed in Table 2. The doses in this table are expressed in mouse intraperitoneal units, in which one unit is the mouse LD₅₀ dose by that route of administration. Whereas for BTX-A and BTX-B toxicity by the various routes is of the same order of magnitude, the type E toxin appeared to be much less toxic. Although no information about the bacterial source strains, level of purification, or pretreatment was provided, the difference is presumably due—at least in part—to the amount of nicking in the tested toxins. Type A toxin is always nicked by the organisms, type B may be (depending on whether the source strain was proteolytic or not), and type E toxin is not nicked endogenously.

In another report, using type B toxin crudely purified from a nonproteolytic strain (the toxin was therefore presumably mostly in an unnicked form), another comparison of route of administration versus test species was made (72). The results are summarized in Table 3. The data from this study suggest that the relative oral potency of this toxin preparation may have been much greater than for the toxin preparation cited by Lamanna. This may reflect the amount of nicking of the toxin (by the oral route, the toxin may have become activated in the gastrointestinal tract, while less activation occurred after parenteral administration).

No primate toxicity data for type B toxin were found in the literature, other than a single-animal, single-dose report. In this study, it was reported that for rhesus monkeys, oral administration of 100 guinea pig minimum lethal dose (least amount that will kill a 350 g guinea pig in 96 hours after subcutaneous injection) was lethal within 24 hours.

As part of our studies evaluating the effects of BTX-B in normal nonhuman primates, we also evaluated the potential toxicity of doses 10 to 20 times those that effectively paralyzed muscles. In these studies, the toxin was injected intramuscularly, in doses divided over five different muscles: the trapezius, abductor pollicis brevis, extensor digitorum brevis, gluteus maximus, and biceps femoris. Doses in this phase of the study ranged from total body doses of 120 to 480 U/kg total body weight. Toxicity was evaluated by clinical observations, clinical chemistries, ophthalmoscopic evaluations, electrocardiograms, and electrophysiological measurements: changes in peak evoked compound muscle action potential of muscles not injected with the drug (expected to be reduced if system weakening was caused by the drug), nerve conduction velocities of peripheral motor and sensory nerves (expected to change as a result of distal myelinopathies and axonopathies), and somatosensory evoked potentials to evaluate potential dysfunction

Table 2 Toxicity of Botulinum Toxins for the Guinea Pig by Various Routes

Type	Mouse intraperitoneal (ip) units		
	ip	oral	respiratory
A	5.2	840	141
B	4.8	413	350
E	78.0	456,000	778

Source: From M.A. Cardella and J.V. Jemski, personal communication, as cited in Ref. 70.

Exper.

Table
and R
neous
Fig M

Specie

Mice
Guinea
Rabbit

Source:

in the
total o
two se
auton
inabili
change
result
toxin i
system
dose o
dose o
to the

CLIN

The re
other
differ
therap
after i
benefi
indica
block
toxins
toxin.
therap
A, the
Wh
have
only
nonhu
tivity
ness a

yer and Selter

A toxin caused
the sensitivities
tested in Table 2.
Each one unit is
A and BTX-B
toxin appeared
trains, level of
se—at least in
nicked by the
proteolytic or

ytic strain (the
reason of route
rized in Table
in preparation
ina. This may
have become
ter parenteral

, other than a
sus monkeys,
hat will kill a
hin 24 hours.
nan primates,
at effectively
urly, in doses
vis, extensor
e of the study
ty was evalu-
tions, electro-
ed compound
be reduced if
of peripheral
opathies and
J dysfunction

Experience with Botulinum Toxin Type B

81

Table 3 Relative Susceptibility of Mice, Guinea Pigs, and Rabbits to Type B Toxin Administered Subcutaneously, or Orally, as Multiples of Number of Guinea Pig Minimum Lethal Subcutaneous Doses

Species	Route of administration	
	Subcutaneous	Oral
Mice	0.2	2
Guinea pigs	1	2
Rabbits	20	100

Source: Based on data from Ref. 72.

in the central nervous system. No signs of toxicity were observed, even after injection of a total of 480 U/kg, either when administered in a single dosing or when administered as two separate doses of 240 U/kg given 11 weeks apart. Specifically, there were no signs of autonomic nervous system deficits, ophthalmic changes, difficulty in swallowing, or inability to maintain normal posture, even at the highest dose tested. Electrocardiographic changes initially observed in a preliminary segment of the study were found to be the result of the ketamine and pentobarbital anesthesia regimen, rather than related to the toxin itself. The EMO studies also did not indicate any central or peripheral neuropathy or systemic muscle weakness, even at the highest doses tested. In one of the test groups, a dose of 240 U/kg was reinjected into the same animals less than 3 months after an initial dose of 240 U/kg. Again, in these animals, no signs of toxicity were observed, according to the measures listed above.

CLINICAL USES OF BOTULINUM TOXIN TYPE B

The relative clinical value of BTX-A and BTX-B in the treatment of cervical dystonia, or other movement disorders, is currently unknown. The structural and pharmacologic differences between the types of toxin, summarized above, suggest that they might not be therapeutically equivalent. Such differences, if real, are likely to be demonstrated only after injection into dystonic muscles. However, even assuming no specific therapeutic benefit of one toxin type over the other, type B toxin could still be useful for this indication. Because the two toxins are antigenically different (antibodies to type A do not block the effects of type B toxin, and vice versa, in animals or in vitro models), the two toxins could be used together, or in rotation, thus reducing antigenic presentation of either toxin. This, in turn, could delay, reduce, or prevent the development of resistance to toxin therapy. In those patients who have already developed resistance to botulinum toxin type A, the type B toxin could provide the best treatment available.

While our studies in nonhuman primates suggest that BTX-B may be effective and have an excellent therapeutic index, the actual effectiveness of this drug can be judged only after use in dystonia patients. The extrapolation of these results from normal nonhuman primates to dystonic humans assumes no major difference in terms of sensitivity to this specific serotype of the toxin, and no unique difference in muscle responsiveness associated with dystonia as opposed to normal muscles.

SUMMARY

The type B botulinum toxin has many biochemical and biological similarities to other serotypes of BTX. At the same time, there are some indications that the type B toxin may have some unique properties that could have beneficial clinical implications. Most obvious of these is that its amino acid sequence is sufficiently different from those of other serotypes that type A-resistant patients may respond to type B. The mechanistic differences in the mode of action of the various types of BTX have not yet been intensively studied under conditions that will allow prediction of clinical benefit (if any) to dystonia patients. Most of these studies to date have been performed in normal rodents or using in vitro/ex vivo models, which, because of interspecies differences in sensitivity to various types of the toxin, may not be directly applicable. Preliminary data from our laboratory, however, suggests that type B toxin effectively paralyzes nonhuman primate muscle after intramuscular injection and is possibly less likely to cause systemic toxicity than type A toxin.

REFERENCES

1. Van Ermengem E. A new anaerobic bacillus and its relation to botulism. *Rev Infect Dis* 1979;1:701-719. (An abridged translation of the original publication, Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. *Z Hyg Infektionskr* 1897;26:1-56.
2. Sakaguchi G. *Clostridium botulinum* toxins. *Pharmacol Ther* 1983;19:165-194.
3. Dolman CE, Murakami L. *Clostridium botulinum* Type F with recent observations on other types. *J Infect Dis* 1961;109:107-128.
4. Kozki S, Sakaguchi S, Sakaguchi G. Purification and some properties of progenitor toxins of *Clostridium botulinum* Type B. *Infect Immun* 1974;10:750-765.
5. Somers E, DasGupta BR. *Clostridium botulinum* Types A, B, C1 and E produce proteins with or without hemagglutinating activity: do they share common amino acid sequences and genes? *J Protein Chem* 1991;10:415-425.
6. Lamanna C, Lowenthal JP. The lack of identity between hemagglutinin and the toxin of Type A botulinum organism. *J Bacteriol* 1951;61:751-752.
7. Sugii S, Ohishi I, Sakaguchi G. Correlation between oral toxicity and in vitro stability of *Clostridium botulinum* type A and B toxins of different molecular sizes. *Infect Immun* 1977;16:910-914.
8. DasGupta BR. Activation of *Clostridium botulinum* Type B toxin by an endogenous enzyme. *J Bacteriol* 1971;108:1051-1057.
9. Tjaberg TB. Proteases of *Clostridium botulinum*. III. Isolation and characterization of proteases from *Clostridium botulinum* Types A, B, C, D, and F. *Acta Vet Scand* 1973;14:538-559.
10. DasGupta BR, Sugiyama H. Molecular form of neurotoxins in proteolytic *Clostridium botulinum* Type B cultures. *Infect Immun* 1976;14:680-686.
11. Sugiyama H, DasGupta BR, Yang KH. Disulfide-toxicity relationship of botulinum toxin Types A, E, and F. *Proc Soc Biol Med* 1973;143:589-591.
12. DasGupta BR, Sugiyama H. Comparative sizes of Type A and B botulinum neurotoxins. *Toxicon* 1977;15:357-363.
13. Schmidt JJ, Sathiyamoorthy V, DasGupta B. Partial amino acid sequences of botulinum neurotoxins B and E. *Arch Biochem Biophys* 1985;238:544-548.
14. DasGupta BR. The structure of botulinum neurotoxin. In: Simpson LL, ed. *Botulinum neurotoxin and tetanus toxin*. San Diego: Academic Press, 1989:53-67.

Experience

15. DasGupta BR. Similar
16. Binz T. Botulinum 1990;2
17. Hathevi. *Clostridium botulinum* 607-61
18. Sakaguchi
19. Halpern. Tetanus 18-22.
20. Whelan. cloning determin
21. Kuraz. Habert toxin a
22. Simpson. cholera
23. Dolly. motor
24. Weds. CC. B. to rat
25. Black. Ultrastr for typ
26. Evans. neurotoxin m
27. Poulet. release toxin 1988;2
28. Kozak. some
29. Bandy. chains 2663.
30. Monte. Biochem
31. Simpson. lipids,
32. Bakry. univer 1991;2
33. Scheer. gangli
34. Kozak. *Clostridium botulinum* and fr

yer and Seiler

Experience with Botulinum Toxin Type B

83

arities to other
pe B toxin may
ications. Most
n those of other
hanistic differ-
ten intensively
ny) to dystonia
nts or using in
ivity to various
our laboratory,
te muscle after
ty than type A

Rev Infect Dis
er cinco neu
nstr 1897;26:1-

194.
vations on other

genitor toxins of

ce proteins with
nces and genes?

ie toxin of Type

thro stability of
Infect Immun

genous enzyme.

rization of pro-
Scand 1973;14:

tic Clostridium

botulinic toxin

um neurotoxins.

s of botulinum

ed. Botulinum

15. DasGupta BR, Datta A. Botulinum neurotoxin type B (strain 657): partial sequence and similarity with tetanus toxin. *Biochemie* 1988;70:811-817.
16. Binz T, Kurazono H, Wille M, Frevert J, Wernars K, Niemann H. The complete sequence of Botulinum neurotoxin Type A and comparison with other clostridial neurotoxins. *J Biol Chem* 1990;265:9153-9158.
17. Hatheway CL, McCroskey LM, Lombard GL, Dowell VR. Atypical toxin variant of *Clostridium botulinum* type B associated with infant botulism. *J Clin Microbiol* 1981;14:607-611.
18. Sakaguchi G. Clostridium botulinum toxins. *Pharmacol Ther* 1983;19:165-194.
19. Halpern JL, Smith LA, Seamon KB, Groover KA, Habig WH. Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody. *Infect Immun* 1989;57:18-22.
20. Whelan SM, Elmore MJ, Bodsworth NJ, Brichm JK, Atkinson T, Minton N. Molecular cloning of the *Clostridium botulinum* structural gene encoding the Type B neurotoxin and determination of its entire nucleotide sequence. *Appl Environ Microbiol* 1992;58:2345-2354.
21. Kurazono H, Mochida S, Binz T, Eisel U, Quantz M, Grebenstein O, Wernars K, Poulain B, Haberman H. Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin Type A. *J Biol Chem* 1992;267:14721-14729.
22. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. *J Pharmacol Exp Ther* 1980;224:135-140.
23. Dolly JO, Black JD, Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. *Nature* 1984;307:457-460.
24. Wadsworth DF, Desai M, Tranter HS, King HJ, Hambleton P, Melling J, Dolly JO, Shone CC. Botulinum type F neurotoxin. Large-scale purification and characterization of its binding to rat cerebrocortical synaptosomes. *Biochem J* 1990;268:123-128.
25. Black JD, Dolly JO. Interaction of ¹²⁵I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. *J Cell Biol* 1986;103:521-534.
26. Evans DM, Williams RS, Shone CC, Hambleton P, Melling J, Dolly JO. Botulinum neurotoxin type B. Its purification, radioiodination and interaction with rat-brain synaptosomal membranes. *Eur J Biochem* 1986;154:409-416.
27. Poulain B, Taux L, Maisrey EA, Wadsworth JDF, Mohan PM, Dolly JO. Neurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chain. *Proc Natl Acad Sci USA* 1988;85:4090-4094.
28. Kozaki S. Interaction of botulinum toxin Type A, B, and E derivative toxins with synaptosomes of rat brain. *Naunyn-Schmiedeberg Arch Pharmacol* 1979;308:67-70.
29. Bandyopadhyay S, Clark AW, DasGupta BR, Sathyamoorthy V. Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. *J Biol Chem* 1987;262:2660-2663.
30. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes? *Trends Biochem Sci* 1986;11:314-317.
31. Simpson LL, Rapport MM. The binding of botulinum toxin to membrane lipids: sphingolipids, steroids and fatty acids. *J Neurochem* 1971;18:1751-1759.
32. Bakry N, Kamata Y, Simpson LL. Lectins from *Triticum vulgaris* and *Limax flavus* are universal antagonists of botulinum neurotoxin and tetanus toxin. *J Pharmacol Exp Ther* 1991;258:830-836.
33. Schengrund C-L, DasGupta BR, Ringler NJ. Binding of botulinum and tetanus neurotoxins to ganglioside GT 1b and derivatives thereof. *J Neurochem* 1991;57:1024-1032.
34. Kozaki S, Ogawara J, Shimoto Y, Kamata Y, Sakaguchi G. Antigenic structure of Clostridium botulinum Type B neurotoxin and its interaction with gangliosides, cerebroside and free fatty acids. *Infect Immun* 1987;55:3051-3056.

35. Shone CC, Hambleton P. Toxicogenic clostridia. In: Minton NP, Clarke DJ, Eds. *Clostridia*. New York: Plenum Press, 1989:265-292.
36. Malsey EA, Wadsworth JDF, Poulain B, Shone CC, Melling J, Gibbs P, Tanc L, Dolly JO. Involvement of the constituent chains of botulinum neurotoxins A and B in the blockade of neurotransmitter release. *Eur J Biochem* 1988;177:683-691.
37. Stiecher B, Weller U, Habermann E, Gratzl M, Ahnert-Hilger G. The light chain but not the heavy chain of botulinum A toxin inhibits exocytosis from permeabilized adrenal chromaffin cells. *FEBS Lett* 1989;255:391-394.
38. Simpson LL. The interaction between divalent cations and botulinum toxin Type A in the paralysis of the rat phrenic nerve-hemidiaphragm preparations. *Neuropharmacology* 1973;12:165-176.
39. Simpson LL. Kinetic studies on the interaction of botulinum toxin type A and the cholinergic neuromuscular junction. *J Pharmacol Exp Ther* 1980;212:16-21.
40. Montecucco C, Shlavo G, DasGupta B. Effect of pH on the interaction of botulinum neurotoxins A, B, and E with liposomes. *Biochem J* 1989;259:47-53.
41. Hoch DH, Romero-Mira M, Ehrlich BE, Finkelstein A, DasGupta BR, Simpson LL. Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes. *Proc Natl Acad Sci USA* 1985;82:1692-1696.
42. Bittner MA, DasGupta BR, Holtz RW. Isolated light chains of botulinum neurotoxins inhibit exocytosis. Studies in digitonin-permeabilized chromaffin cells. *J Biol Chem* 1989;264:10354-10360.
43. Simpson LL. Targeting drugs and toxins to the brain: magic bullets. *Int Rev Neurobiol* 1988;30:123-147.
44. Ashton AC, Edwards K, Dolly JO. Lack of detectable ADP-ribosylation in synaptosomes associated with inhibition of transmitter release by botulinum neurotoxins A and B. *Biochem Soc Trans* 1988;16:883-884.
45. Niemann H, Bintz T, Crebenstein O, Kawazono H, Thierier J, Mochida S, Poulain B, Lauce L. Clostridial neurotoxins: from toxins to therapeutic tools? *Behring Inst Mitt* 1991;89:153-162.
46. Bhattacharyya SD, Sugiyama H. Inactivation of botulinum and tetanus toxins by chelators. *Infect Immun* 1989;57:3053-3057.
47. Gensel M, Penner R, Dreyer F. Distinct sites of action of clostridial neurotoxins revealed by double-poisoning of mouse motor nerve terminals. *Pflügers Arch* 1987;409:533-539.
48. Molgo J, DasGupta BR, Thesleff S. Characterization of the actions of botulinum neurotoxin type E at the rat neuromuscular junction. *Acta Physiol Scand* 1989;137:497-501.
49. Ashton AC, Dolly JO. Microtubule-dissociating drugs and A23187 reveal differences in the inhibition of synaptosomal transmitter release by botulinum neurotoxins types A and B. *J Neurochem* 1991;56:827-835.
50. Simpson LL. Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins. *J Pharmacol Exp Ther* 1988;245:867-872.
51. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. *J Physiol* 1949;109:10-24.
52. Sellin LC, Thesleff S, DasGupta BR. Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction. *Acta Physiol Scand* 1983;119:127-133.
53. Sellin LC, Kauffman JA, DasGupta BR. Comparison of the effects of botulinum neurotoxins types A and E at the rat neuromuscular junction. *Med Biol* 1983;61:120-125.
54. Kauffman JA, Way JF, Siegel LS, Sellin LC. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. *Toxicol Appl Pharmacol* 1985;79:211-217.
55. Duchon LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end plates of slow and fast skeletal muscle fibres of the mouse. *J Neurol Sci* 1971;14:47-60.

56. Diaz J
57. Speno
58. Alden
59. Schar
60. Tacke
61. Hugel
62. Temar
63. Long
64. Donad
65. Cheriv
66. Picket
67. Jablec
68. Martir
69. Wrigh
70. Lamm
71. Legros
72. Guml

oyer and Settle

Eds. *Clostridia*.

Leuc L, Dolly JO.
n the blockade of

chain but not the
drenal chromaffin

in Type A in the
uropharmacology

nd the cholinergic

ion of botulinum

nson LL. Chan-
yers: relevance to
5;82:1692-1696.
eurotoxins inhibit
Chem 1989;264:

1 Rev Neurobiol

in synaptosomes
and B. Biochem

olain B, Leuc L.
991;89:153-162.
rins by chelators.

oxins revealed by
9:533-539.

linum neurotoxins
97-501.

differences in the
ypes A and B. J

biologic activity

e neuro-muscular

botulinum toxin on
83;119:127-133.

inum neurotoxins
-125.

of types A and F
col 1985;79:211-

linum toxin in the
se. J Neurol Sci

Experience with Botulinum Toxin Type B

85

56. Diaz J, Molgó J, Pérot-Dechavassine M. Sprouting of frog motor nerve terminals after long-term paralysis by botulinum type A toxin. *Neurosci Lett* 1989;96:127-132.
57. Spencer RF, McNeer KW. Botulinum toxin paralysis of adult monkey extracocular muscle. *Arch Ophthalmol* 1987;105:1703-1711.
58. Alderson K, Holdis JB, Anderson RL. Botulinum-induced alterations of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. *Neurology* 1991;41:1800-1805.
59. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. *Microbiol Rev* 1992;56:80-99.
60. Tacket CO, Rogawski MA. Botulism. In: Simpson LL, ed. *Botulinum neurotoxin and tetanus toxin*. San Diego: Academic Press, 1989:351-378.
61. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR, Gangarosa EJ. Clinical features of types A and B food-borne botulism. *Ann Intern Med* 1981;95:442-445.
62. Ternanova W, Palumbo JN, Bremen JG. Ocular findings in botulism Type B. *JAMA* 1979;241:475-477.
63. Long SS, Gajewski JL, Brown LW, Gilligan PH. Clinical, laboratory and environmental features of infant botulism in southeastern Pennsylvania. *Pediatrics* 1985;75:935-941.
64. Donadio JM, Gangarosa EJ, Faich GA. Diagnosis and treatment of botulism. *J Infect Dis* 1971;124:108-112.
65. Cherington M. Electrophysiologic methods as an aid in diagnosis of botulism: a review. *Muscle Nerve* 1982;6:528-529.
66. Pickett J, Berg B, Chaplin E, Brunstetter-Shafer M-A. Syndrome of botulism in infancy: clinical and electrophysiological studies. *N Engl J Med* 1976;295:770-772.
67. Jablonski CK. Electrodiagnostic evaluation of patients with myasthenia gravis and related disorders. *Neurol Clin* 1985;3:557-572.
68. Martinez AC, Anciones B, Ferrer MT, Díez Tejedor E, Pérez Conde MC, Bescansa E. Electrophysiologic study in benign human botulism type B. *Muscle Nerve* 1985;8:580-585.
69. Wright GP. The neurotoxins of *Clostridium botulinum* and *Clostridium tetani*. *Pharmacol Rev* 1955;7:413-464.
70. Lamanna C. Immunological aspects of airborne infections: some general considerations of response to inhalation of toxins. *Bacteriol Rev* 1961;25:323-330.
71. Legroux R, Levaditi JC, Héramet C. Influence de voies d'introduction de la toxine sur le botulisme expérimentale du lapin. *Ann Inst. Pasteur* 1945;71:490-493.
72. Gunnison JB, Meyer KF. Susceptibility of monkeys, goats, and small animals to oral administration of botulinum toxin, types B, C, and D. *J Infect Dis* 1930;46:335-340.